Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases

Frits Thorsen, Brett Fite, Lisa M. Mahakian, Jai Seo, Shengping Qin, Victoria Harrison, Sarah Johnson, Elizabeth Ingham, Charles Caskey, Terje Sundstrøm, Thomas J. Meade, Patrick N. Harter, Kai Ove Skaftnesmo, Katherine W. Ferrara

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Our goal was to develop strategies to quantify the accumulation of model therapeutics in small brain metastases using multimodal imaging, in order to enhance the potential for successful treatment. Human melanoma cells were injected into the left cardiac ventricle of immunodeficient mice. Bioluminescent, MR and PET imaging were applied to evaluate the limits of detection and potential for contrast agent extravasation in small brain metastases. A pharmacokinetic model was applied to estimate vascular permeability. Bioluminescent imaging after injecting d-luciferin (molecular weight (MW) 320 D) suggested that tumor cell extravasation had already occurred at week 1, which was confirmed by histology. 7 T T1w MRI at week 4 was able to detect non-leaky 100 μm sized lesions and leaky tumors with diameters down to 200 μm after contrast injection at week 5. PET imaging showed that 18F-FLT (MW 244 Da) accumulated in the brain at week 4. Gadolinium-based MRI tracers (MW 559 Da and 2.066 kDa) extravasated after 5 weeks (tumor diameter 600 μm), and the lower MW agent cleared more rapidly from the tumor (mean apparent permeabilities 2.27 × 10- 5 cm/s versus 1.12 × 10- 5 cm/s). PET imaging further demonstrated tumor permeability to 64Cu-BSA (MW 65.55 kDa) at week 6 (tumor diameter 700 μm). In conclusion, high field T1w MRI without contrast may improve the detection limit of small brain metastases, allowing for earlier diagnosis of patients, although the smallest lesions detected with T1w MRI were permeable only to d-luciferin and the amphipathic small molecule 18F-FLT. Different-sized MR and PET contrast agents demonstrated the gradual increase in leakiness of the blood tumor barrier during metastatic progression, which could guide clinicians in choosing tailored treatment strategies.

Original languageEnglish (US)
Pages (from-to)812-822
Number of pages11
JournalJournal of Controlled Release
Volume172
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Multimodal Imaging
Brain Neoplasms
Permeability
Neoplasm Metastasis
Molecular Weight
Neoplasms
Brain
Contrast Media
Heart Ventricles
Limit of Detection
Gadolinium
Capillary Permeability
Early Diagnosis
Melanoma
Histology
Therapeutics
Pharmacokinetics
Injections

Keywords

  • Bioluminescence imaging
  • Brain metastasis
  • Contrast agents
  • MRI
  • PET

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases. / Thorsen, Frits; Fite, Brett; Mahakian, Lisa M.; Seo, Jai; Qin, Shengping; Harrison, Victoria; Johnson, Sarah; Ingham, Elizabeth; Caskey, Charles; Sundstrøm, Terje; Meade, Thomas J.; Harter, Patrick N.; Skaftnesmo, Kai Ove; Ferrara, Katherine W.

In: Journal of Controlled Release, Vol. 172, No. 3, 2013, p. 812-822.

Research output: Contribution to journalArticle

Thorsen, F, Fite, B, Mahakian, LM, Seo, J, Qin, S, Harrison, V, Johnson, S, Ingham, E, Caskey, C, Sundstrøm, T, Meade, TJ, Harter, PN, Skaftnesmo, KO & Ferrara, KW 2013, 'Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases', Journal of Controlled Release, vol. 172, no. 3, pp. 812-822. https://doi.org/10.1016/j.jconrel.2013.10.019
Thorsen, Frits ; Fite, Brett ; Mahakian, Lisa M. ; Seo, Jai ; Qin, Shengping ; Harrison, Victoria ; Johnson, Sarah ; Ingham, Elizabeth ; Caskey, Charles ; Sundstrøm, Terje ; Meade, Thomas J. ; Harter, Patrick N. ; Skaftnesmo, Kai Ove ; Ferrara, Katherine W. / Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases. In: Journal of Controlled Release. 2013 ; Vol. 172, No. 3. pp. 812-822.
@article{86dcf7b9ec704aa783d7a4ed0cf5ac80,
title = "Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases",
abstract = "Our goal was to develop strategies to quantify the accumulation of model therapeutics in small brain metastases using multimodal imaging, in order to enhance the potential for successful treatment. Human melanoma cells were injected into the left cardiac ventricle of immunodeficient mice. Bioluminescent, MR and PET imaging were applied to evaluate the limits of detection and potential for contrast agent extravasation in small brain metastases. A pharmacokinetic model was applied to estimate vascular permeability. Bioluminescent imaging after injecting d-luciferin (molecular weight (MW) 320 D) suggested that tumor cell extravasation had already occurred at week 1, which was confirmed by histology. 7 T T1w MRI at week 4 was able to detect non-leaky 100 μm sized lesions and leaky tumors with diameters down to 200 μm after contrast injection at week 5. PET imaging showed that 18F-FLT (MW 244 Da) accumulated in the brain at week 4. Gadolinium-based MRI tracers (MW 559 Da and 2.066 kDa) extravasated after 5 weeks (tumor diameter 600 μm), and the lower MW agent cleared more rapidly from the tumor (mean apparent permeabilities 2.27 × 10- 5 cm/s versus 1.12 × 10- 5 cm/s). PET imaging further demonstrated tumor permeability to 64Cu-BSA (MW 65.55 kDa) at week 6 (tumor diameter 700 μm). In conclusion, high field T1w MRI without contrast may improve the detection limit of small brain metastases, allowing for earlier diagnosis of patients, although the smallest lesions detected with T1w MRI were permeable only to d-luciferin and the amphipathic small molecule 18F-FLT. Different-sized MR and PET contrast agents demonstrated the gradual increase in leakiness of the blood tumor barrier during metastatic progression, which could guide clinicians in choosing tailored treatment strategies.",
keywords = "Bioluminescence imaging, Brain metastasis, Contrast agents, MRI, PET",
author = "Frits Thorsen and Brett Fite and Mahakian, {Lisa M.} and Jai Seo and Shengping Qin and Victoria Harrison and Sarah Johnson and Elizabeth Ingham and Charles Caskey and Terje Sundstr{\o}m and Meade, {Thomas J.} and Harter, {Patrick N.} and Skaftnesmo, {Kai Ove} and Ferrara, {Katherine W.}",
year = "2013",
doi = "10.1016/j.jconrel.2013.10.019",
language = "English (US)",
volume = "172",
pages = "812--822",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases

AU - Thorsen, Frits

AU - Fite, Brett

AU - Mahakian, Lisa M.

AU - Seo, Jai

AU - Qin, Shengping

AU - Harrison, Victoria

AU - Johnson, Sarah

AU - Ingham, Elizabeth

AU - Caskey, Charles

AU - Sundstrøm, Terje

AU - Meade, Thomas J.

AU - Harter, Patrick N.

AU - Skaftnesmo, Kai Ove

AU - Ferrara, Katherine W.

PY - 2013

Y1 - 2013

N2 - Our goal was to develop strategies to quantify the accumulation of model therapeutics in small brain metastases using multimodal imaging, in order to enhance the potential for successful treatment. Human melanoma cells were injected into the left cardiac ventricle of immunodeficient mice. Bioluminescent, MR and PET imaging were applied to evaluate the limits of detection and potential for contrast agent extravasation in small brain metastases. A pharmacokinetic model was applied to estimate vascular permeability. Bioluminescent imaging after injecting d-luciferin (molecular weight (MW) 320 D) suggested that tumor cell extravasation had already occurred at week 1, which was confirmed by histology. 7 T T1w MRI at week 4 was able to detect non-leaky 100 μm sized lesions and leaky tumors with diameters down to 200 μm after contrast injection at week 5. PET imaging showed that 18F-FLT (MW 244 Da) accumulated in the brain at week 4. Gadolinium-based MRI tracers (MW 559 Da and 2.066 kDa) extravasated after 5 weeks (tumor diameter 600 μm), and the lower MW agent cleared more rapidly from the tumor (mean apparent permeabilities 2.27 × 10- 5 cm/s versus 1.12 × 10- 5 cm/s). PET imaging further demonstrated tumor permeability to 64Cu-BSA (MW 65.55 kDa) at week 6 (tumor diameter 700 μm). In conclusion, high field T1w MRI without contrast may improve the detection limit of small brain metastases, allowing for earlier diagnosis of patients, although the smallest lesions detected with T1w MRI were permeable only to d-luciferin and the amphipathic small molecule 18F-FLT. Different-sized MR and PET contrast agents demonstrated the gradual increase in leakiness of the blood tumor barrier during metastatic progression, which could guide clinicians in choosing tailored treatment strategies.

AB - Our goal was to develop strategies to quantify the accumulation of model therapeutics in small brain metastases using multimodal imaging, in order to enhance the potential for successful treatment. Human melanoma cells were injected into the left cardiac ventricle of immunodeficient mice. Bioluminescent, MR and PET imaging were applied to evaluate the limits of detection and potential for contrast agent extravasation in small brain metastases. A pharmacokinetic model was applied to estimate vascular permeability. Bioluminescent imaging after injecting d-luciferin (molecular weight (MW) 320 D) suggested that tumor cell extravasation had already occurred at week 1, which was confirmed by histology. 7 T T1w MRI at week 4 was able to detect non-leaky 100 μm sized lesions and leaky tumors with diameters down to 200 μm after contrast injection at week 5. PET imaging showed that 18F-FLT (MW 244 Da) accumulated in the brain at week 4. Gadolinium-based MRI tracers (MW 559 Da and 2.066 kDa) extravasated after 5 weeks (tumor diameter 600 μm), and the lower MW agent cleared more rapidly from the tumor (mean apparent permeabilities 2.27 × 10- 5 cm/s versus 1.12 × 10- 5 cm/s). PET imaging further demonstrated tumor permeability to 64Cu-BSA (MW 65.55 kDa) at week 6 (tumor diameter 700 μm). In conclusion, high field T1w MRI without contrast may improve the detection limit of small brain metastases, allowing for earlier diagnosis of patients, although the smallest lesions detected with T1w MRI were permeable only to d-luciferin and the amphipathic small molecule 18F-FLT. Different-sized MR and PET contrast agents demonstrated the gradual increase in leakiness of the blood tumor barrier during metastatic progression, which could guide clinicians in choosing tailored treatment strategies.

KW - Bioluminescence imaging

KW - Brain metastasis

KW - Contrast agents

KW - MRI

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=84887173106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887173106&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2013.10.019

DO - 10.1016/j.jconrel.2013.10.019

M3 - Article

C2 - 24161382

AN - SCOPUS:84887173106

VL - 172

SP - 812

EP - 822

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -